<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572413</url>
  </required_header>
  <id_info>
    <org_study_id>NL65290.091.18 substudy</org_study_id>
    <nct_id>NCT03572413</nct_id>
  </id_info>
  <brief_title>The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.</brief_title>
  <acronym>RECOVER-PLUS</acronym>
  <official_title>The Effectiveness of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery in Preserving Innate Immune Homeostasis by Reducing Peritoneal Mesothelial Cell Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Substudy of the RECOVER trial (a randomised controlled trial comparing the effect of low&#xD;
      pressure pneumoperitoneum with deep neuromuscular block versus normal pressure&#xD;
      pneumoperitoneum with moderate neuromuscular block during laparoscopic colorectal surgery on&#xD;
      early quality of recovery) investigating innate immune homeostasis after laparoscopic&#xD;
      colorectal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: increased intra-abdominal pressure can cause peritoneal mesothelial cell injury&#xD;
      either directly or by compression of the capillary vessels, causing a variable degree of&#xD;
      ischemia reperfusion injury. The immune system can identify damage to host cells by&#xD;
      recognising Danger-Associated Molecular Patterns (DAMPs) that are released upon cell death in&#xD;
      an uncontrolled fashion, such as during surgical trauma. DAMPs elicit an immune response&#xD;
      similar to the response to invading pathogens and induce an anti-inflammatory immune response&#xD;
      strongly related to postoperative recovery, infectious complications and mortality. Low&#xD;
      pressure PNP is associated with lower levels of serum pro- and anti-inflammatory cytokines&#xD;
      and better preservation of innate immune function.&#xD;
&#xD;
      Objective: to establish the relationship between the use of low pressure pneumoperitoneum&#xD;
      with deep neuromuscular blockade and innate immune function after laparoscopic colorectal&#xD;
      surgery.&#xD;
&#xD;
      Study design: a multi-center, blinded, randomized controlled clinical trial.&#xD;
&#xD;
      Study population: adult individuals scheduled for laparoscopic colorectal surgery with a&#xD;
      primary colonic anastomosis.&#xD;
&#xD;
      Intervention: participants will be randomly assigned in a 1:1 fashion to either the&#xD;
      experimental group (group A): low pressure PNP (8 mmHg) with deep NMB (PTC 1-2) or the&#xD;
      control group (group B): normal pressure PNP (12 mmHg) with moderate NMB (TOF count 1-2).&#xD;
&#xD;
      Primary endpoint: mononuclear cell responsiveness ex-vivo as reflected by TNFα release upon&#xD;
      LPS stimulation.&#xD;
&#xD;
      Secondary endpoints: mononuclear cell responsiveness ex-vivo as reflected by IL-6, IL-10 and&#xD;
      IL-1beta release upon LPS stimulation. Peritoneal mesothelial hypoxia as reflected by&#xD;
      peritoneal HIF1α mRNA expression, histological peritoneal mesothelial cell injury and plasma&#xD;
      levels of DAMPs and cytokines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mononuclear cell responsiveness ex vivo</measure>
    <time_frame>Before surgery, 24 and 72 hours after surgery</time_frame>
    <description>TNFalpha release upon LPS stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mononuclear cell responsiveness ex-vivo</measure>
    <time_frame>Before surgery, 24 and 72 hours after surgery</time_frame>
    <description>IL-6, IL-10 and IL-1beta release upon LPS stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum DAMPs and cytokines</measure>
    <time_frame>Before surgery, at the end of surgery and 24 hours after surgery</time_frame>
    <description>Danger associated molecular patterns, TNFalpha, IL-6 and IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA-DR mRNA expression</measure>
    <time_frame>Before surgery, 24 and 72 hours after surgery</time_frame>
    <description>MHC-II antigen presenting immune receptor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal histology and HIF1alpha expression</measure>
    <time_frame>At the start and end of surgery</time_frame>
    <description>Histology and HIF1alpha mRNA expression of a peritoneal biopsy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pneumoperitoneum</condition>
  <condition>Neuromuscular Blockade</condition>
  <condition>Surgery</condition>
  <condition>Immune Suppression</condition>
  <arm_group>
    <arm_group_label>Low pressure PNP, deep NMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal pressure PNP, moderate NMB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low pressure pneumoperitoneum</intervention_name>
    <description>Lowering intra-abdominal pressure during laparoscopic surgery</description>
    <arm_group_label>Low pressure PNP, deep NMB</arm_group_label>
    <other_name>Low intra-abdominal pressure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide</intervention_name>
    <description>Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block</description>
    <arm_group_label>Low pressure PNP, deep NMB</arm_group_label>
    <arm_group_label>Normal pressure PNP, moderate NMB</arm_group_label>
    <other_name>Deep muscle relaxation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for laparoscopic colorectal surgery with a primary anastomosis&#xD;
&#xD;
          -  Obtained informed consent&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient control of the Dutch language to read the patient information and to fill&#xD;
             out the questionnaires&#xD;
&#xD;
          -  Primary colostomy&#xD;
&#xD;
          -  Neo-adjuvant chemotherapy&#xD;
&#xD;
          -  Chronic use of analgesics or psychotropic drugs&#xD;
&#xD;
          -  Use of NSAIDs shorter than 5 days before surgery&#xD;
&#xD;
          -  Known or suspected allergy to rocuronium of sugammadex&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Indication for rapid sequence induction&#xD;
&#xD;
          -  Severe liver- or renal disease (creatinine clearance &lt;30ml/min)&#xD;
&#xD;
          -  BMI &gt;35 kg/m²&#xD;
&#xD;
          -  Deficiency of vitamin K dependent clotting factors or coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim I Albers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiel C Warlé, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Deep neuromuscular block</keyword>
  <keyword>Low pressure pneumoperitoneum</keyword>
  <keyword>Postoperative immune suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumoperitoneum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

